- Lamevudine
-
- $5.00 / 5KG
-
2019-08-06
- CAS:443642-29-3
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 1ton
|
| | 7-Deaza-2'-C-methyladenosine Basic information |
| Product Name: | 7-Deaza-2'-C-methyladenosine | | Synonyms: | 7-(2-C-Methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine;2'-b-C-methyl tubercidin;Lamevudine;7-Deaza-2'-C-methyladenosine;(2R,3R,4R,5R)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyltetrahydrofuran-3,4-diol;(2R,3R,4R,5R)-2-(4-aMino-7H-pyrrolo[2,3-d]pyriMidin-7-yl)-5-(hyd;MK-0608;7H-PYRROLO[2,3-D]PYRIMIDIN-4-A | | CAS: | 443642-29-3 | | MF: | C12H16N4O4 | | MW: | 280.28 | | EINECS: | 200-001-2 | | Product Categories: | | | Mol File: | 443642-29-3.mol |  |
| | 7-Deaza-2'-C-methyladenosine Chemical Properties |
| Melting point | 222 °C(Solv: methanol (67-56-1); acetonitrile (75-05-8)) | | Boiling point | 620.7±55.0 °C(Predicted) | | density | 1.75±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: Slightly soluble: 0.1-1 mg/ml | | form | Solid | | pka | 12.51±0.70(Predicted) | | color | White to off-white | | InChI | InChI=1/C12H16N4O4/c1-12(19)8(18)7(4-17)20-11(12)16-3-2-6-9(13)14-5-15-10(6)16/h2-3,5,7-8,11,17-19H,4H2,1H3,(H2,13,14,15)/t7-,8-,11-,12-/s3 | | InChIKey | IRZRJANZDIOOIF-ULJXVLPWNA-N | | SMILES | C[C@]1([C@@H]([C@@H](CO)O[C@H]1N1C=CC2=C(N=CN=C12)N)O)O |&1:1,2,3,7,r| |
| | 7-Deaza-2'-C-methyladenosine Usage And Synthesis |
| Uses | 7-Deaza-2''-C-methyladenosine is a hepatitis C virus (HCV) polymerase inhibitor. | | Definition |
MK 0608 (7-Deaza-2'-C-methyladenosine) is an anti-viral agent against Hepatitis C Virus (HCV). It has been shown to inhibit viral RNA replication in the subgenomic HCV genotype 1b replicon, with a 50% effective concentration (EC50) of 0.3 μM (EC90 = 1.3 μM). To determine efficacy in vivo, MK-0608 was administered to HCV-infected chimpanzees, resulting in dose- and time-dependent decreases in plasma viral loads. In separate experiments, chimpanzees dosed for 7 days with MK-0608 at 0.2 and 2 mg per kg of body weight per day by intravenous administration experienced average reductions in viral load of 1.0 and >5 log10 IU/ml, respectively.
| | in vivo | Oral dosing of MK-0608 results in a potent antiviral effect. In preclinical pharmacokinetic experiments with rats, dogs, and rhesus monkeys, MK-0608 demonstrates good to excellent oral bioavailability (50 to 100%) and long plasma half-lives in dogs and rhesus macaques (9 and 14 h, respectively)[1]. | Animal Model: | The HCV-infected chimpanzees[1] | | Dosage: | 1 mg/kg | | Administration: | Administered orally; once daily for 37 days | | Result: | Chimpanzee X6 had a baseline viral load that varied from 1,110 to 12,900 IU/mL, and chimpanzee X4 had a baseline viral load of 3×106 to 9×106 IU/mL. |
| | Solubility in organics | Soluble in DMSO, not in water.
| | storage |
Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20 ℃ for long term (months to years).
| | References | [1] DAVID B OLSEN. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties.[J]. Antimicrobial Agents and Chemotherapy, 2004, 48 10: 3944-3953. DOI: 10.1128/aac.48.10.3944-3953.2004
[2] JOANNA ŻMURKO. The Viral Polymerase Inhibitor 7-Deaza-2’-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model[J]. PLoS Neglected Tropical Diseases, 2016, 10 1. DOI: 10.1101/041905 |
| | 7-Deaza-2'-C-methyladenosine Preparation Products And Raw materials |
|